November 18th, 2024: Ratio Enters License and Collaboration …

5 days ago · Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid …

CouponFollow Extension

$745
OFF

Novartis Taps Ratio For $745M Radiopharmaceutical Pact

6 days from now

Nov 15, 2024 · Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics.

fiercebiotech.com

$750
OFF

Ratio Nets Potential $750M Radioligand Cancer Deal With Novartis

6 days from now

4 days ago · Ratio Therapeutics has inked a deal potentially worth $745M with Novartis for the development of a radiotherapeutic candidate for cancer.

insideprecisionmedicine.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class …

yahoo.com

$50
OFF

Ratio Therapeutics Secures Funds For Cancer Radiotherapies

6 days from now

Jan 18, 2024 · Ratio Therapeutics has secured $50m in a Series B financing round, a significant move aimed at advancing targeted radiotherapies for cancer treatment. The funding, which …

pharmaceutical-technology.com

$20
OFF

Ratio Therapeutics Announces $20M Series A Financing To …

6 days from now

BOSTON, Feb. 1, 2023 /PRNewswire/ -- Ratio Therapeutics Inc., a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, …

prnewswire.com

$20
OFF

Ratio Raises $20m To Build On Its Radiopharma Ambitions

6 days from now

2 days ago · Boston-based biotech Ratio Therapeutics has doubled its funding at a stroke with a $20 million Series A that will be used to usher its targeted radiotherapies into clinical testing.

pharmaphorum.com

$55
OFF

Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market

6 days from now

1 day ago · In an interview with Endpoints News, however, management confirmed that the buyout could hit $1.1 billion in both upfront and milestone payments. ... The Kate acquisition …

biospace.com

6%
OFF

Novartis Raises Sales Outlook For Mid-Term, Acquires Kate …

6 days from now

7 hours ago · NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene …

nasdaq.com

$1
OFF

Novartis Acquires Kate Therapeutics To Advance Gene Therapies

6 days from now

1 day ago · Novartis has announced the acquisition of San Diego-based Kate Therapeutics in a deal valued at $1.1bn, enhancing its portfolio of gene therapies for inherited neuromuscular …

pharmaceutical-technology.com

FAQs about November 18th, 2024: Ratio Enters License and Collaboration … Coupon?

What is Novartis doing with ratio Therapeutics?

Novartis also entered into an exclusive worldwide license and collaboration agreement with Ratio Therapeutics Inc. for a next-generation SSTR2-targeting radiotherapeutic candidate, which adds to the company’s deep radioligand therapy pipeline. ...

Why did Novartis acquire Kate Therapeutics?

This acquisition follows Novartis’ recent collaboration with Ratio Therapeutics to develop a radiotherapeutic targeting somatostatin receptor 2 for cancer treatment. "Novartis acquires Kate Therapeutics to advance gene therapies" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. ...

Who is Kate Therapeutics?

Kate Therapeutics is a preclinical-stage biotechnology company that focuses on adeno-associated virus (AAV)-based gene therapies. The acquisition adds the company’s preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy and myotonic dystrophy type 1 to Novartis' portfolio. ...

Why did Novartis increase its sales guidance in 2023-2028?

Novartis NVS announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with the previous estimate of 5%. The rise in guidance was due to the strong momentum of NVS’ key drugs and its upcoming launches. ...

What is radiopharmaceutical therapy?

Radiopharmaceutical therapy involves targeting cancer cells with a radioactive drug. Credit: elenabsl via Shutterstock.© elenabsl via Shutterstock. Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance radiopharmaceutical therapies. ...

What is ratio & how does it work?

Ratio brings innovation to the table through its proprietary Trillium and Macropa platforms, which use alpha particles’ tumour-killing properties to develop tuneable radiopharmaceuticals. These platforms aim to expand the range of solid tumours that can be targeted. ...